Greater rates of patients with PsO achieved concurrent complete skin and nail clearance with bimekizumab vs adalimumab, ustekinumab, and secukinumab.

On November 6, 2025, Hikma Pharmaceuticals PLC, and its subsidiary Hikma Pharmaceuticals USA Inc., announced the launch of ...

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

Anticipation surrounds Roivant Sciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter. New inv ...

Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA ®, a biosimilar to Stelara (ustekinumab) 1, in Europe. The ...